Integral Diagnostics (IDX.AX) Saham Harga

Integral Diagnostics Harga

ASX·DITUTUP
2,09
​
Pasar ditutup

Selama 14 tahun terakhir pendapatan Integral Diagnostics tumbuh 48,9% per tahun, mencapai 788,62 Juta. AUD. Laba per saham tumbuh 15,9% per tahun selama 13 tahun terakhir. Bagi Integral Diagnostics, margin bersih sebesar 2,8% turun dibanding 4,1% beberapa tahun lalu. Pada harga saat ini imbal hasil dividen sekitar 4,31%. Rasio pembayaran sekitar 330% dari laba. Dividen tumbuh 5,0% per tahun selama 10 tahun terakhir. Target harga konsensus 12 bulan untuk Integral Diagnostics adalah 3,37 AUD, sekitar di atas harga saat ini 61,1%. Dari 16 analis, 14 merekomendasikan beli — konsensus keseluruhan Beli.

Harga saham Integral Diagnostics

Akses data ini lewat Eulerpool API

100.000 permintaan/bulan gratis · tanpa kartu

Model bisnis dan analisis saham Integral Diagnostics

Integral Diagnostics Ltd adalah perusahaan Australia yang telah menyediakan layanan pencitraan medis selama lebih dari 25 tahun. Perusahaan ini didirikan pada tahun 1994 oleh Dr. Ian Kadish dan sebuah tim radiolog di Perth, Australia Barat, dengan menawarkan layanan radiologi kepada klinik dan rumah sakit setempat. Seiring berjalannya waktu, Integral Diagnostics telah memperluas layanannya untuk menyediakan layanan pencitraan di seluruh negara. Model bisnis Integral Diagnostics adalah memberikan pencitraan medis guna memungkinkan dokter dan pasien mereka mendapatkan diagnosis yang cepat dan akurat. Perusahaan ini menawarkan layanan pencitraan untuk berbagai spesialisasi medis, termasuk radiologi, kardiologi, obstetri dan ginekologi, serta neurologi. Mereka mengoperasikan lebih dari 49 lokasi di Australia, banyak di antaranya berada di daerah pedesaan di mana akses terhadap perawatan medis mungkin terbatas. Integral Diagnostics menawarkan beragam produk berbasis pencitraan medis. Produk-produk tersebut meliputi sinar-X, mamografi, ultrasound, pemindaian CT, MRI, PET, dan pemindaian kepadatan tulang. Perusahaan ini bangga menjadi salah satu dari sedikit perusahaan pencitraan medis di Australia yang menawarkan rangkaian lengkap layanan pencitraan. Layanan mereka dilakukan oleh radiolog berkualifikasi yang berspesialisasi dalam menafsirkan gambar medis. Integral Diagnostics juga mengoperasikan klinik untuk melakukan prosedur diagnostik dan terapeutik seperti biopsi, drainase, dan injeksi. Prosedur-prosedur ini dilakukan oleh radiolog yang sangat berkualitas untuk memberikan pasien diagnosis yang lebih cepat dan akurat. Integral Diagnostics berkomitmen pada jaminan mutu dan memiliki sistem manajemen mutu yang komprehensif yang ditinjau secara tahunan oleh auditor independen. Perusahaan ini terakreditasi oleh Asosiasi Medis Australia (Australian Medical Association) dan Skema Akreditasi Nasional Australia (NATA). Akreditasi-akreditasi ini mengakui standar tinggi yang ditetapkan oleh Integral Diagnostics dalam penyediaan layanan pencitraan medis. Salah satu aktivitas terbaru Integral Diagnostics adalah penggunaan kecerdasan buatan (AI) dalam penafsiran gambar. Perusahaan ini telah bermitra dengan MaxQ AI, penyedia solusi AI terkemuka untuk pencitraan medis. Melalui kemitraan ini, dokter di Integral Diagnostics dapat memanfaatkan alat AI terkini untuk meningkatkan diagnosis bagi pasien mereka. Integral Diagnostics merupakan pendukung kuat keadilan sosial dan berdedikasi untuk mendukung komunitas yang kurang beruntung di Australia. Perusahaan ini telah bermitra dengan organisasi nirlaba seperti National Breast Cancer Foundation, The Smith Family, dan Friendship Foundation. Secara keseluruhan, Integral Diagnostics telah mengalami pertumbuhan yang mengesankan selama 25 tahun terakhir dan kini merupakan perusahaan pencitraan medis terkemuka di Australia. Dengan beragam layanan pencitraan dan fokus kuat pada kualitas serta tanggung jawab sosial, perusahaan ini berada dalam posisi yang baik untuk melanjutkan kesuksesan di masa depan.

Pertanyaan yang sering diajukan tentang saham Integral Diagnostics

The business model of Integral Diagnostics Ltd is focused on providing comprehensive diagnostic imaging services to the medical industry. They operate a network of medical imaging clinics across Australia, offering a wide range of imaging services such as MRI, CT, ultrasound, and X-ray scans. Integral Diagnostics aims to deliver high-quality radiology services, ensuring accurate and timely diagnosis for patients. Through their state-of-the-art facilities and experienced medical professionals, they aim to consistently meet the growing demand for advanced imaging services. Integral Diagnostics Ltd aims to enhance patient care and support healthcare providers in delivering effective treatment plans.

Integral Diagnostics Ltd is primarily active in the healthcare industry. With a focus on precision radiology, the company provides a broad range of diagnostic imaging services including X-rays, ultrasounds, CT scans, and more. Integral Diagnostics operates in various sectors within healthcare, including hospitals, medical centers, and specialty clinics. With their high-quality imaging equipment and expert radiologists, Integral Diagnostics plays a crucial role in assisting healthcare professionals in accurate and timely diagnoses. As a leading player in the healthcare industry, Integral Diagnostics Ltd continues to contribute to the advancement of medical imaging and patient care.

The main competitors of Integral Diagnostics Ltd in the market include companies like Sonic Healthcare Ltd, Healius Ltd, and Capitol Health Ltd.

Integral Diagnostics Ltd is a leading medical imaging and radiology service provider in Australia and New Zealand. Established in 2008, the company has quickly grown to become a trusted name in the healthcare industry. With a strong focus on delivering high-quality diagnostic services, Integral Diagnostics utilizes advanced imaging technologies to assist in the accurate detection and diagnosis of various medical conditions. The company prides itself on its team of expert radiologists and state-of-the-art facilities, ensuring patients receive the best possible care. Integral Diagnostics continues to expand its network of clinics, striving to make diagnostic services more accessible to patients across the region.

Integral Diagnostics Ltd has achieved several significant milestones since its establishment. The company has successfully expanded its services and reach, becoming one of the leading providers of radiology and nuclear medicine services in Australia and New Zealand. Integral Diagnostics Ltd has also demonstrated consistent growth and financial success over the years. Additionally, the company has made strategic acquisitions, such as Cape Radiology and Global Diagnostics, further strengthening its position in the market. Integral Diagnostics Ltd continues to invest in advanced technology and quality patient care, striving to deliver exceptional diagnostic imaging services to its customers.

Integral Diagnostics Ltd is primarily present in Australia and New Zealand.

Integral Diagnostics Ltd represents values of excellence, innovation, and integrity. With a strong corporate philosophy emphasizing patient care and diagnostic accuracy, Integral Diagnostics aims to provide the highest quality medical imaging and radiology services. The company's commitment to advanced technology and continuous improvement ensures accurate diagnoses, timely results, and exceptional patient outcomes. By investing in cutting-edge equipment, fostering a collaborative environment, and prioritizing professional development, Integral Diagnostics maintains its status as a trusted provider in the medical imaging field. With a focus on patient-centric care, the company consistently delivers superior diagnostic services, making it a preferred choice for medical professionals and patients alike.

Analis saat ini menetapkan target harga rata-rata 3,34 AUD untuk saham Integral Diagnostics (median: 3,37 AUD), yaitu +59,6 % terhadap harga terbaru. Konsensus didasarkan pada 16 peringkat analis.

16 analis saat ini menilai saham Integral Diagnostics: 14 merekomendasikan beli, 1 tahan, dan 1 jual.

Dengan kurs saat ini, saham Integral Diagnostics diperdagangkan pada 1,31 EUR (2,09 AUD).

Saham Integral Diagnostics (IDX.AX) tercatat di 1 bursa, termasuk: ASX (IDX.AX).

Integral Diagnostics Ltd is a leading Australian diagnostic company that offers medical imaging and pathology services. The company was founded in 1998 and has been listed on the Australian stock exchange since 2015. Integral Diagnostics' business model is based on providing high-quality diagnostic services needed by physicians and other healthcare providers to make accurate diagnoses and ensure the best possible treatment for their patients. Integral Diagnostics operates several business divisions, including radiology services, pathology services, and clinical trials. In the radiology field, the company offers a wide range of diagnostic imaging services, including X-rays, ultrasound, MRI, and CT scans. The company has over 50 radiology practices throughout Australia and a growing presence in New Zealand. The company also offers specialized radiology services such as oncology imaging and intervention, as well as training and workshops for medical staff. Integral Diagnostics also operates a pathology division, which offers a comprehensive range of pathology services including clinical chemistry, hematology, histopathology, and microbiological testing. Integral Diagnostics' pathology services are used for diagnosing diseases and monitoring patients undergoing treatment. In the pathology division, Integral Diagnostics operates 17 laboratories throughout Australia. In addition to radiology and pathology services, Integral Diagnostics also conducts clinical trials. The company provides support to medical researchers in conducting clinical trials and evaluating the effectiveness of new treatment methods. Integral Diagnostics' clinical trials cover a wide range of medical specialties, including oncology, cardiology, and neurology. Integral Diagnostics has a robust IT system that allows for the electronic transmission of patient data and images. The company also operates an online platform through which physicians and medical professionals can access their patient data and images. This facilitates information exchange among doctors and enables quicker diagnosis and treatment of patients. Integral Diagnostics' business model is based on providing high-quality and efficient diagnostic services. The products offered by Integral Diagnostics are essential tools for physicians and medical professionals to make accurate diagnoses and ensure the best possible treatment for patients. When it comes to search engine optimization (SEO), it is important to use relevant keywords that users enter when searching for medical diagnostic services. These may include keywords such as "radiology services," "pathology services," and "clinical trials." The text should also provide the reader with a clear overview of Integral Diagnostics' business model without being too promotional.

Pendapatan dari Integral Diagnostics adalah 788,62 Juta. AUD. Angka ini didasarkan pada data keuangan terkini dan mencerminkan kinerja bisnis perusahaan.

Laba dari Integral Diagnostics adalah 21,93 Juta. AUD. Laba bersih mencerminkan profitabilitas perusahaan setelah mengurangi semua biaya.

Rasio harga-terhadap-pendapatan (PER) Integral Diagnostics saat ini adalah 35,91. PER membandingkan harga saham saat ini dengan laba per saham dan membantu investor menilai valuasi saham Integral Diagnostics.

Rasio harga-terhadap-penjualan (PSR) Integral Diagnostics saat ini adalah 1,00. PSR membandingkan kapitalisasi pasar dengan pendapatan tahunan dan berfungsi sebagai metrik valuasi untuk saham Integral Diagnostics.

Skor Kualitas AlleAktien untuk Integral Diagnostics adalah 6/10.

ISIN dari Integral Diagnostics adalah AU000000IDX2. ISIN (International Securities Identification Number) adalah identifikasi unik global untuk sekuritas.

Ticker dari Integral Diagnostics adalah IDX.AX. Simbol ticker digunakan untuk memperdagangkan saham Integral Diagnostics di bursa saham.

Nilai WajarTerminal
1,86 AUD
Penilaian Berlebihan/KurangTerminal
Dinilai secara wajar
Sektor
Industri
Penyedia Layanan Kesehatan & Jasa
Jumlah Saham
Karyawan
Pendapatan per Karyawan
422.172,91 AUD
Pertumbuhan Pendapatan Ø5 Tahun
Pertumbuhan EBIT Ø5 Tahun
Pertumbuhan Laba Bersih Ø5 Tahun
Negara
Australia
Mata Uang
AUD
Penawaran Umum Perdana
21 Okt 2015
ISIN
AU000000IDX2
CUSIP
Q4936S101
SEDOL
BYV2ZK7
Kapitalisasi Pasar
Kisaran 52 Minggu
Rasio PEG
2,48
P/E 2027
15,80
P/E 2028
13,22
P/E 2029
11,99
P/E 2030
10,24
P/E 2031
8,03
P/S
P/S
0,94
EV/EBIT
17,65
Rasio P/B
0,96
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
1,72 %
Dividen
Hasil dividen
4,31 %
Hasil Dividen Estimasi
5,74 %
Rasio Pembayaran
329,61 %
Pertumbuhan dividen Ø5T
-2,05 %
Pembayaran dividen per tahun
2
Dividen dibayarkan sejak
10 tahun
Dividen tidak dipotong sejak
1 tahun
Dividen meningkat sejak
1 tahun
Pajak penahan dividen
30,00 %
Terakhir diperbarui 26 Okt 2026, 13.49

Kelompok Peer Integral Diagnostics

Integral Diagnostics Ticker

ASX · IDX.AX

Integral Diagnostics FIGI

IDX:AU · BBG00B2FQPN0IDX:AT · BBG00B2FTPW7IDX:AH · BBG00B2FTQ00ITGDF:US · BBG00Z4K5G02ITGDF:PQ · BBG00Z4K5GF6ITGDF:UV · BBG00Z4K5GG5